비알코올성 지방간염(NASH) 시장 : 시장 분석 및 예측 - 유형별, 제품별, 서비스별, 기술별, 용도별, 최종 사용자별, 스테이지별, 모드별, 컴포넌트별, 솔루션별(-2035년)

Non-Alcoholic Steatohepatitis (NASH) Market is anticipated to expand from $8.36 billion in 2024 to $111.26 billion by 2034, growing at a CAGR of approximately 29.5%. The Non-Alcoholic Steatohepatitis (NASH) Market encompasses therapeutics targeting liver inflammation and damage due to fat accumulation, excluding alcohol-related causes. This burgeoning sector is driven by rising obesity and diabetes rates, with significant R&D investment in novel drug classes like FXR agonists and anti-fibrotic agents. The market is poised for growth as awareness and diagnostic advancements increase, offering lucrative opportunities for pharmaceutical innovation.

The Non-Alcoholic Steatohepatitis (NASH) Market is poised for significant growth, driven by rising awareness and increasing incidence of liver-related disorders. Within the treatment segment, the pharmaceuticals sub-segment is the top performer, with a focus on anti-fibrotic and metabolic drugs showing promising therapeutic outcomes. Innovative drug classes such as FXR agonists and PPAR agonists are gaining traction, reflecting their potential in addressing disease pathology. The diagnostics segment is also witnessing robust growth, with non-invasive tests leading due to their patient-friendly nature and accuracy. Among diagnostics, imaging techniques like elastography are emerging as the second highest performing sub-segment, offering precise liver fibrosis assessment. The growing emphasis on early detection and personalized medicine is fostering advancements in biomarker discovery. Collaborative research initiatives and strategic partnerships among key industry players are accelerating innovation. As the market evolves, the integration of digital health technologies is expected to enhance patient management and treatment adherence.

Market Snapshot:

The Non-Alcoholic Steatohepatitis (NASH) market is witnessing dynamic shifts in market share, pricing strategies, and new product launches. Leading pharmaceutical companies are strategically enhancing their portfolios to capture greater market share. Pricing remains competitive, influenced by innovative treatment options entering the market. New product launches are frequent, driven by advancements in research and development. These innovations aim to address unmet clinical needs, offering promising therapeutic solutions. The market is characterized by a robust pipeline of drugs, with several candidates in advanced stages of clinical trials. Competition within the NASH market is intense, with key players vying for dominance. Benchmarking reveals a landscape where strategic collaborations and partnerships are pivotal. Regulatory influences play a crucial role, with agencies in North America and Europe setting stringent guidelines that shape market dynamics. Regulatory approvals are critical milestones that impact market entry and expansion. The competitive environment is further complicated by the need for compliance with evolving healthcare policies, which affect drug pricing and reimbursement.

Geographical Overview:

The Non-Alcoholic Steatohepatitis (NASH) market is witnessing notable growth across various regions, each showcasing unique opportunities. North America leads the market, driven by a high prevalence of obesity and diabetes, which are major risk factors for NASH. The region's advanced healthcare infrastructure and strong focus on research and development further bolster its market position. Europe follows closely, with increasing awareness and early diagnosis initiatives contributing to market growth. The region's emphasis on innovative therapeutics and supportive regulatory frameworks enhances its appeal. In the Asia Pacific, the market is expanding rapidly, fueled by rising healthcare expenditure and a growing patient pool. Countries like China and India are emerging as key growth pockets due to increasing prevalence rates and improving healthcare access. Latin America and the Middle East & Africa present emerging opportunities. Latin America's market is driven by rising healthcare investments, while the Middle East & Africa are recognizing the significance of addressing NASH to mitigate associated healthcare burdens.

Key Trends and Drivers:

The Non-Alcoholic Steatohepatitis (NASH) market is experiencing substantial growth driven by increasing prevalence of obesity and diabetes. These conditions are major risk factors for NASH, leading to a rising incidence rate globally. Key trends include advancements in diagnostic technologies, enabling earlier and more accurate detection of NASH. This is crucial as early-stage intervention can significantly alter disease progression and patient outcomes. Pharmaceutical companies are investing heavily in research and development to discover effective therapeutic options. The pipeline is robust, with numerous drugs in various stages of clinical trials. This surge in R&D activity is a critical driver of market expansion. Additionally, there is a growing collaboration between biotech firms and academic institutions, fostering innovation and accelerating drug development timelines. Awareness campaigns about liver health and NASH are gaining traction, contributing to increased diagnosis rates. This is coupled with a greater emphasis on lifestyle modifications as part of comprehensive treatment plans. Opportunities abound in developing regions where healthcare infrastructure is improving, and access to advanced diagnostics is expanding. Companies that can provide cost-effective and scalable solutions stand to gain a competitive edge in these emerging markets.

Restraints and Challenges:

The Non-Alcoholic Steatohepatitis (NASH) market encounters several significant restraints and challenges. A primary challenge is the complexity of accurately diagnosing NASH, which often requires invasive liver biopsies that deter widespread screening and early detection. Additionally, there is a limited understanding of the disease's pathophysiology, complicating the development of targeted therapies and prolonging the drug approval process. The market also suffers from a lack of effective biomarkers, hindering the ability to monitor disease progression and treatment efficacy. Furthermore, the high cost of potential therapies may restrict access, especially in low- and middle-income countries, thus limiting market expansion. Regulatory hurdles present another challenge, as stringent approval processes and varying international regulations can delay the introduction of new treatments. Lastly, competition from alternative therapies and lifestyle interventions poses a threat, as patients and healthcare providers may opt for less costly or invasive options.

Key Players:

Intercept Pharmaceuticals, Genfit, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Viking Therapeutics, Akero Therapeutics, Terns Pharmaceuticals, 89bio, Enyo Pharma, Inventiva, NorthSea Therapeutics, NGM Biopharmaceuticals, Gilead Sciences, Allergan, Conatus Pharmaceuticals, Zydus Cadila, Hepion Pharmaceuticals, Galectin Therapeutics, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Services
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Stage
• 2.8 Key Market Highlights by Mode
• 2.9 Key Market Highlights by Component
• 2.10 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Therapeutics
  • 4.1.2 Diagnostics
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Pharmaceuticals
  • 4.2.2 Biologics
  • 4.2.3 Nutraceuticals
• 4.3 Market Size & Forecast by Services (2020-2035)
  • 4.3.1 Clinical Trials
  • 4.3.2 Consulting Services
  • 4.3.3 Regulatory Services
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Biotechnology
  • 4.4.2 Genomics
  • 4.4.3 Proteomics
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Liver Biopsy
  • 4.5.2 Imaging Techniques
  • 4.5.3 Biomarker Assays
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Research Institutes
  • 4.6.3 Pharmaceutical Companies
• 4.7 Market Size & Forecast by Stage (2020-2035)
  • 4.7.1 Preclinical
  • 4.7.2 Phase I
  • 4.7.3 Phase II
  • 4.7.4 Phase III
• 4.8 Market Size & Forecast by Mode (2020-2035)
  • 4.8.1 Invasive
  • 4.8.2 Non-Invasive
• 4.9 Market Size & Forecast by Component (2020-2035)
  • 4.9.1 Active Pharmaceutical Ingredients
  • 4.9.2 Excipients
• 4.10 Market Size & Forecast by Solutions (2020-2035)
  • 4.10.1 Lifestyle Modification
  • 4.10.2 Pharmacotherapy
  • 4.10.3 Surgical Intervention

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Services
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Stage
    • 5.2.1.8 Mode
    • 5.2.1.9 Component
    • 5.2.1.10 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Services
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Stage
    • 5.2.2.8 Mode
    • 5.2.2.9 Component
    • 5.2.2.10 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Services
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Stage
    • 5.2.3.8 Mode
    • 5.2.3.9 Component
    • 5.2.3.10 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Services
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Stage
    • 5.3.1.8 Mode
    • 5.3.1.9 Component
    • 5.3.1.10 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Services
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Stage
    • 5.3.2.8 Mode
    • 5.3.2.9 Component
    • 5.3.2.10 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Services
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Stage
    • 5.3.3.8 Mode
    • 5.3.3.9 Component
    • 5.3.3.10 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Services
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Stage
    • 5.4.1.8 Mode
    • 5.4.1.9 Component
    • 5.4.1.10 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Services
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Stage
    • 5.4.2.8 Mode
    • 5.4.2.9 Component
    • 5.4.2.10 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Services
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Stage
    • 5.4.3.8 Mode
    • 5.4.3.9 Component
    • 5.4.3.10 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Services
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Stage
    • 5.4.4.8 Mode
    • 5.4.4.9 Component
    • 5.4.4.10 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Services
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Stage
    • 5.4.5.8 Mode
    • 5.4.5.9 Component
    • 5.4.5.10 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Services
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Stage
    • 5.4.6.8 Mode
    • 5.4.6.9 Component
    • 5.4.6.10 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Services
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Stage
    • 5.4.7.8 Mode
    • 5.4.7.9 Component
    • 5.4.7.10 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Services
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Stage
    • 5.5.1.8 Mode
    • 5.5.1.9 Component
    • 5.5.1.10 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Services
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Stage
    • 5.5.2.8 Mode
    • 5.5.2.9 Component
    • 5.5.2.10 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Services
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Stage
    • 5.5.3.8 Mode
    • 5.5.3.9 Component
    • 5.5.3.10 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Services
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Stage
    • 5.5.4.8 Mode
    • 5.5.4.9 Component
    • 5.5.4.10 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Services
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Stage
    • 5.5.5.8 Mode
    • 5.5.5.9 Component
    • 5.5.5.10 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Services
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Stage
    • 5.5.6.8 Mode
    • 5.5.6.9 Component
    • 5.5.6.10 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Services
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Stage
    • 5.6.1.8 Mode
    • 5.6.1.9 Component
    • 5.6.1.10 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Services
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Stage
    • 5.6.2.8 Mode
    • 5.6.2.9 Component
    • 5.6.2.10 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Services
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Stage
    • 5.6.3.8 Mode
    • 5.6.3.9 Component
    • 5.6.3.10 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Services
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Stage
    • 5.6.4.8 Mode
    • 5.6.4.9 Component
    • 5.6.4.10 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Services
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Stage
    • 5.6.5.8 Mode
    • 5.6.5.9 Component
    • 5.6.5.10 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Intercept Pharmaceuticals
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Genfit
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Madrigal Pharmaceuticals
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Galmed Pharmaceuticals
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Viking Therapeutics
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Akero Therapeutics
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Terns Pharmaceuticals
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 89bio
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Enyo Pharma
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Inventiva
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 NorthSea Therapeutics
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 NGM Biopharmaceuticals
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Gilead Sciences
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Allergan
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Conatus Pharmaceuticals
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Zydus Cadila
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Hepion Pharmaceuticals
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Galectin Therapeutics
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Alnylam Pharmaceuticals
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Dicerna Pharmaceuticals
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us